Is EQRx, Inc. (EQRX) a Buy, Sell, or Hold?
NASDAQ : EQRX
EQRx, Inc.
$2.34 USD
-$0.05 (-2.09%)
- Volume
- 11.93M
- Average Volume
- 4.5M
- Market Capitalization
- $1.14B
- P/E Ratio
- 5.44
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $4.75
- Year Low
- $1.58
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $27.51
Company Overview
NASDAQ
Melanie I. Nallicheri
Biotechnology
Healthcare
EQRX
362
US
USD
Liquidity Metrics
0.00
27.51
27.51
9.52
0.00
Sales & Valuation
-$
0.00
0.80
-3.95
-0.61
Profitability
$0.43
$205.49M
0.00%
0.00%
14.15%
14.12%
P/E Metrics
5.44
0.00
0.00
Analyst Price Target & Rating
$5.00
$5.00
$5.00
0/5
4 Analysts
-53.20%
Financial Health Scores
9.77
1/9
$1.17B
$1.24B
$69.37M
-$136.79M
Key Metrics (TTM)
$650.25M
0.00
-4.55
27.51
14.15%
30.77%
18.51%
-25.29%
$5.34
0 days
Company Executives
| Name | Title |
|---|---|
| Christian Antoni | Chief Global Devel. Officer |
| Jamilu E. Rubin | Chief Financial Officer and Principal Financial & Accounting Officer |
| Carlos Garcia-Echeverria | Chief of RX Creation |
Poll Results
No votes yet today — be the first to share your view!
About EQRx, Inc. (NASDAQ:EQRX) Stock
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibod ... y undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.
Frequently Asked Questions
-
What is the current EQRx, Inc. (EQRX) stock price?
-
EQRx, Inc.(NASDAQ:EQRX) stock price is $2.34 in the last trading session. During the trading session, EQRX stock reached the peak price of $4.75 while $1.58 was the lowest point it dropped to. The percentage change in EQRX stock occurred in the recent session was --2.09% while the dollar amount for the price change in EQRX stock was -$0.05.
-
EQRX's industry and sector of operation?
-
The NASDAQ listed EQRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EQRX?
-
Christian Antoni | Chief Global Devel. Officer
Jamilu E. Rubin | Chief Financial Officer and Principal Financial & Accounting Officer
Carlos Garcia-Echeverria | Chief of RX Creation
|
| -
How many employees does EQRX have?
-
Number of EQRX employees currently stands at 362. EQRX operates from 50 Hampshire Street, Cambridge, MA 02139, US.
-
Link for EQRX official website?
-
Official Website of EQRX is: https://www.eqrx.com
-
How do I contact EQRX?
-
EQRX could be contacted at phone #617 315 2255 and can also be accessed through its website. EQRX operates from 50 Hampshire Street, Cambridge, MA 02139, US.
-
How many shares of EQRX are traded daily?
-
The average number of EQRX shares traded daily for last 3 months was 4.5M.
-
What is the market cap of EQRX currently?
-
The market value of EQRX currently stands at $1.14B with its latest stock price at $2.34